BioSpace News Archive

Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, announced that it has received a second Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application seeking approval for IV tramadol.

Landos Biopharma, Inc. announced the successful outcome of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for omilancor, its lead candidate in late-stage clinical development for the treatment of mild-to-moderate active ulcerative colitis patients.

iTeos Therapeutics and GlaxoSmithKline plc announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer.

Mindset Pharma Inc., a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, and InterVivo Solutions, announced the availability of their first data set as part of the Cooperative Psychedelics Evaluation Platform program.

Humana Inc. today announced that it has signed a definitive agreement to acquire One Homecare Solutions (“onehome”) from WayPoint Capital Partners (WayPoint).

Apollo Endosurgery, Inc. announced that investigators of the Multi-Center ESG Randomized Interventional (MERIT) study have reported based on a preliminary analysis the successful achievement of the study’s primary endpoints.

Harrow Health, Inc., an ophthalmic-focused healthcare company, announced that it has commenced an underwritten registered public offering of $17.5 million aggregate principal amount of its 8.625% senior notes due 2026, subject to market and certain other conditions.

Sonnet BioTherapeutics Holdings, Inc., announced today that it has changed the date of its upcoming annual meeting of stockholders from June 24, 2021 to Thursday July 15, 2021 at 9:00 a.m., Eastern Time.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, and James Levine, Chief Financial Officer, will participate in investor meetings at the Raymond James Human Health Innovation Conference